(7/9) About 28,000 people in the U.S. are diagnosed each year with NRAS-mutant solid tumors, including #melanoma, #NSCLC and #CRC. Existing treatments either target all RAS proteins (pan-RAS), or target other downstream parts of the pathway, which leads to significant off-target toxicity and limits efficacy. We have created the first NRAS-selective inhibitor, which has been designed to address the liabilities of current pan-RAS inhibitors by only binding to NRAS. We expect to initiate clinical development of this inhibitor in the second half of 2025.
Relay Therapeutics’ Post
More Relevant Posts
-
Opna’s Bernice Matusow, MS, presented research yesterday at AACR on OPN-6602, our EP300/CBP bromodomain inhibitor, which demonstrated potent anti-tumor activity in preclinical models of multiple myeloma. OPN-6602 significantly reduced tumor growth as a single agent (71% tumor growth inhibition) in the OPM-2 human multiple myeloma cell xenograft model as well as increased anti-tumor activity (>100% TGI) in combination studies. Opna plans to initiate a Phase 1 clinical study with OPN-6602 in multiple myeloma patients later this summer. #AACR #multiplemyeloma#Phase1
-
-
Immuneering! IMRX! Read below! Novel drug discovery!
We are pleased to announce that we have received IND clearance from the FDA for IMM-6-415, paving the way for the initiation of a Phase 1/2a clinical trial for the treatment of advanced RAF or RAS mutant solid tumors. We look forward to advancing this important program for solid tumor patients with any mutation in RAF, KRAS, NRAS, or HRAS into the clinic, with plans to begin dosing in early 2024. For details, see our press release: https://lnkd.in/ekjBT7hc #KRASmutations #RASmutations #TargetedOncology #MAPKPathway #SolidTumors #DrugDiscovery #CancerResearch #MetastaticCancer #AdvancedCancer
-
-
New #JITC article: AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors Monash Health https://bit.ly/46YEIsE
-
-
CEO Nexosome Oncology....Executive, Translational Medicine, Cancer Biology, Diagnostics, Proteomics
Excited to head to my favorite meeting #ASCO with some of the Nexosome Oncology team. Looking forward to catching up with friends, old and new, and continuing to push the envelope to develop better liquid biopsy proteomic technologies to enhance detection of precancerous and early stage tumors. Happy to share more details at #ASCO or email me todd@nexosome-oncology.com to learn more! #liquidbiopsy #proteomics
-
-
Transarterial chemoembolization plus sorafenib as postop adjuvant therapy in patients with hepatocellular carcinoma with portal vein tumor thrombus resulted in longer recurrence-free survival & overall survival than sorafenib alone. https://ja.ma/3VPibMB
-
-
Want to hear the latest in #PrecisionOncology? Join us for a webinar with CAP TODAY to learn more about the implementation of an FDA-cleared tumor profiling assay to enable localized testing for patients.
-
🔬 A recent study on peptide receptor radionuclide therapy (#PRRT) in gastroenteropancreatic neuroendocrine tumor (#GEP-NET) patients provides insights into predictive factors influencing treatment outcomes. 📊Patients receiving a minimal C1 dose of 35 Gy across all target lesions exhibited significantly prolonged progression-free survival (48.1 vs. 26.2 mo). 📉A volumetric decrease in somatostatin receptor (SSTR) tumor volume by more than 10% after the first PRRT cycle correlated with extended PFS (51.3 vs. 22.8 mo). Read the full article here: https://ow.ly/vvnN50QyrI2 #MedEd
-
-
We note the publication of information on the generation and preclinical evaluation of ABBV-184, a novel TCR/anti-CD3 bispecific composed of a highly selective soluble TCR that binds a peptide derived from the oncogene survivin (BIRC5) bound to the class I MHC allele human leukocyte antigen (HLA)-A*02:01 expressed on tumor cells, linked to a specific binder to the CD3 receptor on T cells. We also note, however, that the Phase 1 clinical study of ABBV-184 has been terminated for strategic reasons. https://lnkd.in/eVyRX3dK https://lnkd.in/eQgt5RDU
ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies
aacrjournals.org
-
Discover the potential of TCR-engineered T cells! Shown to be a promising therapeutic strategy that mobilizes T cells to target specific neoantigens on tumor cells, our catalog offers an exclusive range of cell lines that can support your research! #drugdiscovery #TCR #celllines https://hubs.ly/Q02c1khf0
-
-
Oncology-Principal Scientist | Sr. Dir., Medical Affairs | Medical Science Liaison | Doctoral Trained Certified Physician Assistant/Associate | Clinician | Leader | Educator | Life-Long Learner
Want to hear the latest in #PrecisionOncology? Join us for a webinar with CAP TODAY to learn more about the implementation of an FDA-cleared tumor profiling assay to enable localized testing for patients.
CAP TODAY/Labcorp Webinar: Implementation of FDA-cleared tumor profiling assay to enable localized Precision Oncology testing for patients | CAP Today Webinars
learn-more.com
Director of Interior Design, Senior Vice President and Principal at SMMA | Symmes Maini & McKee Associates
1moExciting! Thank you.